TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06466135: Study of WAL0921 in Patients With Glomerular Kidney Diseases

Sponsor: Walden Biosciences · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 96 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,656,500

Rescue Site Savings

+$1,759,500

Unlock Full NCT06466135 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06466135 Rescue Dossier →